Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Supernus Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc compare based on key financial metrics to determine which better meets your investment needs.

About Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Latest Pharmaceuticals and Supernus Pharmaceuticals, Inc., Jazz Pharmaceuticals plc Stock News

As of August 14, 2026, Supernus Pharmaceuticals, Inc. had a $2.8 billion market capitalization, compared to the Pharmaceuticals median of $587.7 million. Supernus Pharmaceuticals, Inc.’s stock is down 2.9% in 2026, up 1.3% in the previous five trading days and up 13.2% in the past year.

Currently, Supernus Pharmaceuticals, Inc. does not have a price-earnings ratio. Supernus Pharmaceuticals, Inc.’s trailing 12-month revenue is $830.4 million with a -13.2% net profit margin. Year-over-year quarterly sales growth most recently was 32.4%. Analysts expect adjusted earnings to reach $2.565 per share for the current fiscal year. Supernus Pharmaceuticals, Inc. does not currently pay a dividend.

As of August 14, 2026, Jazz Pharmaceuticals plc had a $15.9 billion market cap, putting it in the 83rd percentile of all stocks. Jazz Pharmaceuticals plc’s stock is up 44.1% in 2026, down 4.5% in the previous five trading days and up 109.15% in the past year.

Currently, Jazz Pharmaceuticals plc’s price-earnings ratio is 16.7. Jazz Pharmaceuticals plc’s trailing 12-month revenue is $4.6 billion with a 20.4% net profit margin. Year-over-year quarterly sales growth most recently was 15.5%. Analysts expect adjusted earnings to reach $25.049 per share for the current fiscal year. Jazz Pharmaceuticals plc does not currently pay a dividend.

How We Compare Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc Growth Grades

Company	Ticker	Growth
Supernus Pharmaceuticals, Inc.	SUPN	A
Jazz Pharmaceuticals plc	JAZZ	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Supernus Pharmaceuticals, Inc. has a Growth Score of 95, which is Very Strong. Jazz Pharmaceuticals plc has a Growth Score of 89, which is Very Strong.

The Growth Grade Winner: It’s a Tie!

Looking at the Growth Grade breakdown above, both Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc have a grade of A. For investors who focus solely on a company’s upward growth, further research should be conducted into both companies’ other financial metrics before deciding whether to invest.

Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc’s Momentum Grades

Company	Ticker	Momentum
Supernus Pharmaceuticals, Inc.	SUPN	C
Jazz Pharmaceuticals plc	JAZZ	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Supernus Pharmaceuticals, Inc. has a Momentum Score of 43, which is Average. Jazz Pharmaceuticals plc has a Momentum Score of 84, which is Very Strong.

The Momentum Grade Winner: Jazz Pharmaceuticals plc

As you can clearly see from the Momentum Grade breakdown above, Jazz Pharmaceuticals plc is considered to have stronger momentum compared to Supernus Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Jazz Pharmaceuticals plc could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Supernus Pharmaceuticals, Inc.	SUPN	D
Jazz Pharmaceuticals plc	JAZZ	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Supernus Pharmaceuticals, Inc. has a Earnings Estimate Score of 33, which is Negative. Jazz Pharmaceuticals plc has a Earnings Estimate Score of 38, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Supernus Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Supernus Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc is the better investment when it comes to estimate revisions.

Other Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Supernus Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc Stock?

Overall, Supernus Pharmaceuticals, Inc. stock has a Growth Score of 95, Momentum Score of 43 and Estimate Revisions Score of 33.

Jazz Pharmaceuticals plc stock has a Growth Score of 89, Momentum Score of 84 and Estimate Revisions Score of 38.

Comparing Supernus Pharmaceuticals, Inc. and Jazz Pharmaceuticals plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.